Metabolic Syndrome and Cognitive Trajectories in the Framingham Offspring Study

Katherine J. Bangen, Nicole M. Armstrong, Rhoda Au, Alden L Gross

Research output: Contribution to journalArticle

Abstract

Metabolic syndrome (MetS) has been linked to increased risk of developing cognitive impairment and dementia including Alzheimer's disease. It remains unclear whether and at what stage in the adult lifespan MetS and its components begin to alter the trajectory of cognitive performance. In the present study, 2,892 Framingham Offspring participants completed health assessments every four years since 1971 and underwent repeat neuropsychological testing from 1999 to 2014. We estimated the associations of levels and changes in cognitive trajectories with hazard of MetS using a joint growth/survival model. All models were adjusted for baseline age, sex, education, and smoking status. Findings showed that both mid-life and late-life MetS were associated with lower level of cognitive functioning but not cognitive trajectories. Associations were strongest among those who were nondemented and apolipoprotein (APOE) ϵ4 noncarriers. In addition, individuals with the most rapid cognitive decline were more likely to have MetS. The pattern of results showed that associations between MetS and cognition varied, depending upon whether the sample was stratified by genetic and cognitive status and whether we considered cognitive performance as a continuous variable or examined categorical groupings. Given that mid-life MetS was associated with poorer cognition at age 55, cognitive changes may occur early during the MetS process. Our findings suggest that those with MetS are at greater risk of dementia given their lower level of cognitive functioning and also suggest that MetS may be a risk factor for decline in the absence of known risk factors including the APOE ϵ4 allele.

Original languageEnglish (US)
Pages (from-to)931-943
Number of pages13
JournalJournal of Alzheimer's Disease
Volume71
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Apolipoproteins
Cognition
Dementia
Sex Education
Alzheimer Disease
Joints
Smoking
Alleles
Health
Growth
Cognitive Dysfunction

Keywords

  • Aging
  • Alzheimer's disease
  • apolipoprotein E
  • cognition
  • diabetes
  • metabolic syndrome
  • neuropsychology
  • vascular risk

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Metabolic Syndrome and Cognitive Trajectories in the Framingham Offspring Study. / Bangen, Katherine J.; Armstrong, Nicole M.; Au, Rhoda; Gross, Alden L.

In: Journal of Alzheimer's Disease, Vol. 71, No. 3, 01.01.2019, p. 931-943.

Research output: Contribution to journalArticle

Bangen, Katherine J. ; Armstrong, Nicole M. ; Au, Rhoda ; Gross, Alden L. / Metabolic Syndrome and Cognitive Trajectories in the Framingham Offspring Study. In: Journal of Alzheimer's Disease. 2019 ; Vol. 71, No. 3. pp. 931-943.
@article{a8cad00b09584f1eb9d9f4cbb2ea65a3,
title = "Metabolic Syndrome and Cognitive Trajectories in the Framingham Offspring Study",
abstract = "Metabolic syndrome (MetS) has been linked to increased risk of developing cognitive impairment and dementia including Alzheimer's disease. It remains unclear whether and at what stage in the adult lifespan MetS and its components begin to alter the trajectory of cognitive performance. In the present study, 2,892 Framingham Offspring participants completed health assessments every four years since 1971 and underwent repeat neuropsychological testing from 1999 to 2014. We estimated the associations of levels and changes in cognitive trajectories with hazard of MetS using a joint growth/survival model. All models were adjusted for baseline age, sex, education, and smoking status. Findings showed that both mid-life and late-life MetS were associated with lower level of cognitive functioning but not cognitive trajectories. Associations were strongest among those who were nondemented and apolipoprotein (APOE) ϵ4 noncarriers. In addition, individuals with the most rapid cognitive decline were more likely to have MetS. The pattern of results showed that associations between MetS and cognition varied, depending upon whether the sample was stratified by genetic and cognitive status and whether we considered cognitive performance as a continuous variable or examined categorical groupings. Given that mid-life MetS was associated with poorer cognition at age 55, cognitive changes may occur early during the MetS process. Our findings suggest that those with MetS are at greater risk of dementia given their lower level of cognitive functioning and also suggest that MetS may be a risk factor for decline in the absence of known risk factors including the APOE ϵ4 allele.",
keywords = "Aging, Alzheimer's disease, apolipoprotein E, cognition, diabetes, metabolic syndrome, neuropsychology, vascular risk",
author = "Bangen, {Katherine J.} and Armstrong, {Nicole M.} and Rhoda Au and Gross, {Alden L}",
year = "2019",
month = "1",
day = "1",
doi = "10.3233/JAD-190261",
language = "English (US)",
volume = "71",
pages = "931--943",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Metabolic Syndrome and Cognitive Trajectories in the Framingham Offspring Study

AU - Bangen, Katherine J.

AU - Armstrong, Nicole M.

AU - Au, Rhoda

AU - Gross, Alden L

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Metabolic syndrome (MetS) has been linked to increased risk of developing cognitive impairment and dementia including Alzheimer's disease. It remains unclear whether and at what stage in the adult lifespan MetS and its components begin to alter the trajectory of cognitive performance. In the present study, 2,892 Framingham Offspring participants completed health assessments every four years since 1971 and underwent repeat neuropsychological testing from 1999 to 2014. We estimated the associations of levels and changes in cognitive trajectories with hazard of MetS using a joint growth/survival model. All models were adjusted for baseline age, sex, education, and smoking status. Findings showed that both mid-life and late-life MetS were associated with lower level of cognitive functioning but not cognitive trajectories. Associations were strongest among those who were nondemented and apolipoprotein (APOE) ϵ4 noncarriers. In addition, individuals with the most rapid cognitive decline were more likely to have MetS. The pattern of results showed that associations between MetS and cognition varied, depending upon whether the sample was stratified by genetic and cognitive status and whether we considered cognitive performance as a continuous variable or examined categorical groupings. Given that mid-life MetS was associated with poorer cognition at age 55, cognitive changes may occur early during the MetS process. Our findings suggest that those with MetS are at greater risk of dementia given their lower level of cognitive functioning and also suggest that MetS may be a risk factor for decline in the absence of known risk factors including the APOE ϵ4 allele.

AB - Metabolic syndrome (MetS) has been linked to increased risk of developing cognitive impairment and dementia including Alzheimer's disease. It remains unclear whether and at what stage in the adult lifespan MetS and its components begin to alter the trajectory of cognitive performance. In the present study, 2,892 Framingham Offspring participants completed health assessments every four years since 1971 and underwent repeat neuropsychological testing from 1999 to 2014. We estimated the associations of levels and changes in cognitive trajectories with hazard of MetS using a joint growth/survival model. All models were adjusted for baseline age, sex, education, and smoking status. Findings showed that both mid-life and late-life MetS were associated with lower level of cognitive functioning but not cognitive trajectories. Associations were strongest among those who were nondemented and apolipoprotein (APOE) ϵ4 noncarriers. In addition, individuals with the most rapid cognitive decline were more likely to have MetS. The pattern of results showed that associations between MetS and cognition varied, depending upon whether the sample was stratified by genetic and cognitive status and whether we considered cognitive performance as a continuous variable or examined categorical groupings. Given that mid-life MetS was associated with poorer cognition at age 55, cognitive changes may occur early during the MetS process. Our findings suggest that those with MetS are at greater risk of dementia given their lower level of cognitive functioning and also suggest that MetS may be a risk factor for decline in the absence of known risk factors including the APOE ϵ4 allele.

KW - Aging

KW - Alzheimer's disease

KW - apolipoprotein E

KW - cognition

KW - diabetes

KW - metabolic syndrome

KW - neuropsychology

KW - vascular risk

UR - http://www.scopus.com/inward/record.url?scp=85073083317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073083317&partnerID=8YFLogxK

U2 - 10.3233/JAD-190261

DO - 10.3233/JAD-190261

M3 - Article

C2 - 31450495

AN - SCOPUS:85073083317

VL - 71

SP - 931

EP - 943

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -